Alnylam Pharmaceuticals declares positive Phase 1 results for ALN-APP in Alzheimer's disease study
Pulmatrix submits PUR3100 IND application to US FDA
FDA grants traditional approval for Leqembi as Alzheimer's disease treatment
Bayer Starts Phase III Studies with Investigational Contrast Agent
Acadia Pharmaceuticals Adds Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
FDA advisory committee confirms clinical benefit of Leqembi for early Alzheimer's disease
Padagis launches Tazarotene Gel and Methylphenidate Transdermal System